Avid Bioservices Inc (CDMO)

[entdoc]

A Saturday MD perspective: The phase III abruption tells us what we already knew: ; lung cancer is a bitch, and Bavi did not dent it. You only fully appreciate that when you have it in you hand as a surgeon. Lung cancer is a boulder, a mountain, or a planet compared with an ant-size construct such as bavituimab. And the same can be said for all immunological attacks on far advanced, well-established (end-of-life) lung cancers or other bulky solid cancers. If the side-effect profile from this study is satisfactory we can move forward on something sensible for bavituximab, such as prevention, or possibly its utility in combination with irradiation therapy. Bavituximab will continue to be undervalued until a use is nailed down. Thank God for Avid.